Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļXENE
āļāļ·āđāļāļāļĢāļīāļĐāļąāļXenon Pharmaceuticals Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 17, 2014
āļāļĩāļāļĩāđāļMortimer (Ian C)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ316
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 17
āļāļĩāđāļāļĒāļđāđ3650 Gilmore Way
āđāļĄāļ·āļāļVANCOUVER
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻCanada
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđV5G 4W8
āđāļāļĢāļĻāļąāļāļāđ16044843300
āđāļ§āđāļāđāļāļāđhttps://www.xenon-pharma.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļXENE
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 17, 2014
āļāļĩāļāļĩāđāļMortimer (Ian C)
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
Dr. Gary Patou, M.D.
Independent Director
Dr. Gary Patou, M.D.
Independent Director
Dr. Gary Patou, M.D.
Independent Director
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board